Carotuximab

LOS ANGELES, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces a groundbreaking collaboration with PreCheck Health Services Inc., a CLIA-certified and CAP-accredited clinical laboratory specializing in genetic sequencing. The partnership focuses on the development of companion biomarkers for Kairos Pharma’s cancer therapy, ENV105, which targets prostate and lung cancers. This strategic agreement aims to advance the precision of patient screening and therapy monitoring for Kairos Pharma’s Phase 1 and Phase 2 clinical trials, with the aim of advancing cancer treatment by identifying patients who will benefit most from ENV105. Kairos Pharma and PreCheck Health Services will utilize advanced molecular diagnostics to corroborate and further develop biomarkers previously identified in a Phase 2 clinical trial. These biomarkers are designed to predict patient responses to ENV105 prior to treatment, offering a more personalized approach to cancer care. Under the agreement, PreCheck will analyze biopsy tissues and circulating tumor cells from patients enrolled in Kairos Pharma’s ongoing clinical trials, including a Phase 2 randomized, multi-institutional trial in prostate cancer and a Phase 1 trial in lung cancer. The goal is to confirm the predictive capabilities of these biomarkers and to discover new biomarkers that can identify suitable candidates for the novel therapy. The collaboration will rely on PreCheck’s proprietary SolidTumorCheck+ platform, which allows for gene expression profiling of tumor biopsies. This technology will be employed to examine samples from patients with both lung and prostate cancer. Furthermore, the analysis of circulating tumor cells aims to offer non-invasive insights, potentially leading to the development of liquid biopsy tests for future patient screening and therapy monitoring. Clinical Trials at the Forefront of Oncology Research The biomarkers will be tested in two key clinical trials: NCT05401110: A Phase 1 trial targeting patients with EGFR-driven lung cancer who have developed resistance to osimertinib. Pre-treatment biopsies will undergo somatic gene expression profiling using the SolidTumorCheck+ platform to identify biomarkers that can predict a favorable response to ENV105.NCT05534646: A phase 2 trial for patients with castrate-resistant prostate cancer (CRPC) who have shown resistance to multiple androgen receptor signaling inhibitors. Here, the focus will be on the somatic profiling of circulating tumor cells and tumor biopsies to confirm previously identified biomarkers and identify any new ones tied to ENV105’s efficacy. Both trials aim to integrate cutting-edge biomarker analysis into treatment plans, ensuring that patients most likely to benefit from ENV105 are accurately identified. Development of Companion Diagnostics A companion diagnostic is an FDA-approved test which can identify patients that are most likely to benefit from a therapeutic product. One of the key outcomes of this partnership is the creation of a companion diagnostic for ENV105. PreCheck will develop a three-gene PCR analysis or other genetic tools to predict patient response to the therapy. This diagnostic will seek FDA approval as a critical tool for the identification of suitable patients with prostate or lung cancer, guiding inclusion for treatment in Phase 3 clinical trials. Dr. Neil Bhowmick, Kairos Pharma’s Chief Scientific Officer, expressed optimism about the collaboration, stating, “Leveraging PreCheck’s vast experience in genetic testing provides a considerable advance in the development of our therapies. The integration of their expertise will significantly enhance our ability to identify patients who will benefit from ENV105 and guide the development of non-invasive liquid biopsy tests.” A Step Forward in Cancer Treatment The development of these companion biomarkers is poised to transform how cancer patients, particularly those with resistant forms of prostate and lung cancer, are treated. The integration of biomarkers and liquid biopsy technologies will allow for more precise targeting of therapies, reducing the likelihood of ineffective treatments and increasing the probability of positive outcomes. Dr. John Yu, Kairos Pharma’s CEO, commented, “This collaboration is an exciting step forward for Kairos Pharma. By working with PreCheck Health Services, we are advancing our mission to provide personalized cancer treatment solutions. The biomarkers we develop will enable us to tailor therapies to individual patients, improving their chances of a successful response to ENV105.” About Kairos Pharma Ltd. Based in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. With a diverse pipeline of investigational therapies, the company is committed to reversing the harmful effects of cancer on the body’s immune system and improving patient outcomes through innovative treatment options. For more information, visit kairospharma.com. About PreCheck Health Services Inc. PreCheck Health Services Inc. is a CLIA-certified and CAP-accredited clinical laboratory known for its expertise in genetic sequencing. PreCheck provides advanced diagnostic services to support precision medicine, particularly in the field of oncology. To learn more about their offerings, visit precheckhealth.com. This strategic agreement marks a significant step in the development of personalized cancer therapies, offering hope to patients with prostate and lung cancer who have few remaining treatment options. Through the power of biomarkers and genetic analysis, Kairos Pharma and PreCheck Health Services are working together to shape the future of oncology treatment, with ENV105 leading the way. CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential” or “hopes” or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion of our Phase 1 and Phase 2 clinical trials; our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma’s prospectus filed with the SEC. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments, except as required by U.S. federal securities laws. Contact: CORE IRLouie Tomainvestors@kairospharma.com

上周（9月16日~9月22日），全球生物制药领域有至少4家致力于创新药研发的公司宣布完成新一轮融资。这些最新获得资本市场青睐的新锐公司主要致力于神经系统疾病小分子疗法、癌症细胞疗法、癌症疫苗、新一代干细胞疗法等领域。 9月19日，GC Therapeutics宣布成立，并已完成6500万美元的A轮融资，由Cormorant Asset Management领投，Mubadala Capital、Andreessen Horowitz （a16z） Bio + Health、Medical Excellence Capital、Cercano Management和Pear VC参投，使该公司的总筹资金额达到7500万美元。 GC Therapeutics致力于推进并解锁下一代细胞疗法。该公司的诱导多能干细胞（iPSC）编程平台TFome（转录因子组）由哈佛医学院和Wyss研究所的教授George Church博士的实验室开发，该平台旨在通过一步式工艺以比传统方法快100倍的速度提供基于iPSC的现货型细胞疗法，以提高效力、效率、质量并降低成本，从而彻底改变细胞疗法。该公司最初的管线将专注于胃肠道、神经和免疫疾病。 9月18日，Brenus Pharma公司宣布完成2500万美元的A轮融资，本轮融资由一组法国投资者与比利时投资基金联合领投，将用于资助Brenus公司治疗转移性结直肠癌的首个癌症疫苗候选药物STC-1010的1/2a期临床试验，以及另一种实体肿瘤适应症的第二个候选药物STC-1020的开发。 STC-1010是基于Brenus Pharma开发的STC（Stimulated-Tumor-[ghost]-Cells）技术平台的首个候选疫苗。该平台主要基于对癌症复杂性的深入理解，能够模拟患者肿瘤细胞的复发情况，“教育”患者的免疫系统能够在肿瘤细胞出现时预测、靶向并摧毁它们，从而开发用于癌症一线治疗的癌症疫苗。 9月17日，Nura Bio今日宣布完成6800万美元的A轮扩展融资，将A轮融资总额提升到1.4亿美元。此次融资由创始投资者The Column Group领投，现有投资者Samsara Bio Capital和Euclidean Capital以及新投资者Sanofi Ventures参与。 Nura Bio致力于开发用于治疗衰弱性神经疾病的神经保护小分子疗法。该公司的早期研发管线专注于开发阻止轴突变性和/或调节小胶质细胞对变性和损伤的反应的小分子疗法，目标是在中枢、外周和眼神经系统疾病中提供神经保护。该公司的主打在研疗法NB-4746是一款具有脑渗透性的SARM1抑制剂。SARM1是一种富集于神经元的烟酰胺腺嘌呤二核苷酸（NAD）水解酶，已被证明是重要的轴突内在代谢传感器及轴突退化的核心驱动因素。目前，NB-4746已在健康志愿者中进行的1期临床试验中取得成功。Nura Bio计划于2025年在患者群体中启动1b/2期临床试验。 9月17日，Kairos Pharma宣布以每股4.00美元的发行价完成了其首次公开发行的1550,000股普通股，该公司从此次发行中获得的总收益为620万美元。Kairos Pharma是一家临床阶段的生物制药公司，专注于开发旨在逆转癌症耐药性和免疫抑制的癌症治疗药物。癌症会对药物产生抗药性，并抑制免疫系统。Kairos公司正在开发针对癌症免疫反应中心“检查点”的小分子药物，以及开发一种活化T细胞疗法，可以将患者的T细胞转化为杀伤活化T细胞，以对抗驱动患者癌症的干细胞。 根据新闻稿，本轮融资主要用于推进Kairos Pharma候选产品ENV 105的肺癌1期试验和前列腺癌2期试验，ENV 105旨在逆转肿瘤对药物的耐药性，使药物再次有效；以及推进临床前候选药物，包括KROS 101，一种靶向GITR配体的小分子激动剂，旨在促进T细胞生长和抗癌症的细胞毒性功能。 希望在资本市场的助力下，更多前沿技术和创新疗法可以尽快造福病患。 参考资料： [1]各家公司官网及公开资料 内容来源于网络，如有侵权，请联系删除。